ArticleCancer medicine2026
Survival Outcomes and Sensitivity of PARP Inhibitors in Platinum-Sensitive Ovarian Cancer: A Retrospective Study.
Article in Cancer medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundPoly (ADP-ribose) polymerase inhibitors (PARPi) have reshaped the maintenance treatment of ovarian cancer. However, a significant proportion of patients exhibit primary resistance, highlighting the need for real-world efficacy data and predictive biomarkers, especially in underrepresented populations.
methodsThis retrospective study analyzed 152 Chinese patients with platinum-sensitive ovarian cancer who received maintenance therapy with olaparib or niraparib, either in the first-line (n = 71) or second-/later-line (n = 81) setting. Progression-free survival (PFS), progression-free interval (PFI), and overall survival (OS) were estimated using the Kaplan-Meier method. An objective, data-driven definition of PARPi sensitivity/resistance was established using receiver operating characteristic (ROC) curve analysis of PFS. Exploratory transcriptomic sequencing and immunohistochemistry (IHC) were performed on a subset of tumors to identify molecular correlates of response.
resultsIn the first-line maintenance cohort, median PFS (mPFS) was 54.35 months and median PFI (mPFI) was 49.57 months. In the second-/later-line group, mPFS was 42.53 months and mPFI was 34.87 months. Based on ROC-defined cutoffs (PFS of 11.6 and 11.8 months, respectively), 22.5% and 24.7% of patients were classified as PARPi-resistance in the first- and second-/later-line groups. Patients classified as sensitive consistently demonstrated superior PFS, PFI, and OS. Exploratory molecular analysis implicated the ferroptosis and HIF-1 signaling pathways in the response mechanism, and IHC validation confirmed differential protein expression of TFRC (lower in resistance tumors) and PRNP (higher in resistance tumors).
conclusionsPARPi maintenance therapy demonstrates substantial clinical benefit in real-world Chinese patients with ovarian cancer. However, over 20% exhibit primary resistance. TFRC and PRNP represent promising biomarkers for predicting PARPi sensitivity and warrant further validation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.